MedTrace Logo

Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity

NCT07158177 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-30

No results posted yet for this study

Summary

Retrospective, comparative, interventional, randomized, single-center study, contralateral (the patient's 2 eyes will be implanted: 1 CPO and the other APO) Patients presenting for cataract surgery with a request for presbyopia correction and managed as part of routine clinical practice.

The main aim of the study is to demonstrate that contrast sensitivity is better with the Clareon PanOptix (CPO) intraocular lens (IOL) compared with the AcrySof PanOptix (APO) IOL 3 months after implantation.

Conditions

  • Cataract and IOL Surgery

Interventions

DEVICE

Acrysof™ PanOptix™ toric or not, trifocal IOL CE marked, Alcon company.

both of the patient's eyes will be implanted: 1 CPO and the other APO

DEVICE

Clareon Panoptix

both of the patient's eyes will be implanted: 1 CPO and the other APO

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Dominique MONNET, MD, PhD · Université Paris Cité, Faculté de Santé / UFR de médecine

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-10-15
Completion
2026-10-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07158177 on ClinicalTrials.gov